A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute, Naples
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Carisma Therapeutics Inc
Nimbus Therapeutics
AO GENERIUM
Adaptimmune